Literature DB >> 21602524

A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia.

Aurore Perrot1, Cédric Pionneau, Sophie Nadaud, Frédéric Davi, Véronique Leblond, Frédéric Jacob, Hélène Merle-Béral, Raoul Herbrecht, Marie-Christine Béné, John G Gribben, Seiamak Bahram, Laurent Vallat.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical course with 2 extreme subsets: indolent, ZAP70(-) and mutated immunoglobulin heavy chain gene (M-CLL); and aggressive, ZAP70(+) and unmutated immunoglobulin heavy chain (UM-CLL). Given the long-term suspicion of antigenic stimulation as a primum movens in the disease, the role of the B-cell receptor has been extensively studied in various experimental settings; albeit scarcely in a comparative dynamic proteomic approach. Here we use a quantitative 2-dimensional fluorescence difference gel electrophoresis technology to compare 48 proteomic profiles of the 2 CLL subsets before and after anti-IgM ligation. Differentially expressed proteins were subsequently identified by mass spectrometry. We show that unstimulated M- and UM-CLL cells display distinct proteomic profiles. Furthermore, anti-IgM stimulation induces a specific proteomic response, more pronounced in the more aggressive CLL. Statistical analyses demonstrate several significant protein variations according to stimulation conditions. Finally, we identify an intermediate form of M-CLL cells, with an indolent profile (ZAP70(-)) but sharing aggressive proteomic profiles alike UM-CLL cells. Collectively, this first quantitative and dynamic proteome analysis of CLL further dissects the complex molecular pathway after B-cell receptor stimulation and depicts distinct proteomic profiles, which could lead to novel molecular stratification of the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602524      PMCID: PMC5292594          DOI: 10.1182/blood-2011-02-335125

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.

Authors:  Chrystelle Brignone; Kathleen E Bradley; Alexei F Kisselev; Steven R Grossman
Journal:  Oncogene       Date:  2004-05-20       Impact factor: 9.867

2.  Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells.

Authors:  Laurent D Vallat; Yuhyun Park; Cheng Li; John G Gribben
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

3.  Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia.

Authors:  Valerio Fulci; Sabina Chiaretti; Marina Goldoni; Gianluca Azzalin; Nicoletta Carucci; Simona Tavolaro; Leandro Castellano; Armando Magrelli; Franca Citarella; Monica Messina; Roberta Maggio; Nadia Peragine; Simona Santangelo; Francesca Romana Mauro; Pablo Landgraf; Thomas Tuschl; David B Weir; Minchen Chien; James J Russo; Jingyue Ju; Robert Sheridan; Chris Sander; Mihaela Zavolan; Anna Guarini; Robin Foà; Giuseppe Macino
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

4.  Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Authors:  Aleksandar Petlickovski; Luca Laurenti; Xiaoping Li; Sara Marietti; Patrizia Chiusolo; Simona Sica; Giuseppe Leone; Dimitar G Efremov
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

5.  Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

Authors:  Fiona Murray; Nikos Darzentas; Anastasia Hadzidimitriou; Gerard Tobin; Myriam Boudjogra; Cristina Scielzo; Nikolaos Laoutaris; Karin Karlsson; Fanny Baran-Marzsak; Athanasios Tsaftaris; Carol Moreno; Achilles Anagnostopoulos; Federico Caligaris-Cappio; Dominique Vaur; Christos Ouzounis; Chrysoula Belessi; Paolo Ghia; Fred Davi; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

6.  MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.

Authors:  Manuela Ferracin; Barbara Zagatti; Lara Rizzotto; Francesco Cavazzini; Angelo Veronese; Maria Ciccone; Elena Saccenti; Laura Lupini; Andrea Grilli; Cristiano De Angeli; Massimo Negrini; Antonio Cuneo
Journal:  Mol Cancer       Date:  2010-05-26       Impact factor: 27.401

7.  Characterization and purification of a protein kinase C substrate in human B cells. Identification as lymphocyte-specific protein 1 (LSP1).

Authors:  E Carballo; D Colomer; J L Vives-Corrons; P J Blackshear; J Gil
Journal:  J Immunol       Date:  1996-03-01       Impact factor: 5.422

8.  Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer.

Authors:  Giridhar Mudduluru; Fabian Medved; Rainer Grobholz; Camela Jost; Anette Gruber; Joerg H Leupold; Stefan Post; Aaron Jansen; Nancy H Colburn; Heike Allgayer
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

9.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.

Authors:  E Matutes; K Owusu-Ankomah; R Morilla; J Garcia Marco; A Houlihan; T H Que; D Catovsky
Journal:  Leukemia       Date:  1994-10       Impact factor: 11.528

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  10 in total

1.  Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia.

Authors:  Laurent Vallat; Corey A Kemper; Nicolas Jung; Myriam Maumy-Bertrand; Frédéric Bertrand; Nicolas Meyer; Arnaud Pocheville; John W Fisher; John G Gribben; Seiamak Bahram
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

2.  Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.

Authors:  Harvey E Johnston; Matthew J Carter; Marta Larrayoz; James Clarke; Spiro D Garbis; David Oscier; Jonathan C Strefford; Andrew J Steele; Renata Walewska; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2018-01-24       Impact factor: 5.911

3.  Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.

Authors:  Jason A Dubovsky; Danielle L Chappell; Bonnie K Harrington; Kitty Agrawal; Leslie A Andritsos; Joseph M Flynn; Jeffrey A Jones; Michael E Paulaitis; Brad Bolon; Amy J Johnson; John C Byrd; Natarajan Muthusamy
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

4.  Proteomic changes during B cell maturation: 2D-DIGE approach.

Authors:  Johanna Salonen; Gunilla Rönnholm; Nisse Kalkkinen; Mauno Vihinen
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

5.  Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Authors:  Gina L Eagle; Jianguo Zhuang; Rosalind E Jenkins; Kathleen J Till; Puthen V Jithesh; Ke Lin; Gillian G Johnson; Melanie Oates; Kevin Park; Neil R Kitteringham; Andrew R Pettitt
Journal:  Mol Cell Proteomics       Date:  2015-02-02       Impact factor: 5.911

6.  BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo.

Authors:  Cédric Schleiss; Wassila Ilias; Ouria Tahar; Yonca Güler; Laurent Miguet; Caroline Mayeur-Rousse; Laurent Mauvieux; Luc-Matthieu Fornecker; Elise Toussaint; Raoul Herbrecht; Frédéric Bertrand; Myriam Maumy-Bertrand; Thierry Martin; Sylvie Fournel; Philippe Georgel; Seiamak Bahram; Laurent Vallat
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 7.  The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.

Authors:  Graham Packham; Serge Krysov; Alex Allen; Natalia Savelyeva; Andrew J Steele; Francesco Forconi; Freda K Stevenson
Journal:  Haematologica       Date:  2014-07       Impact factor: 9.941

8.  CLL cells respond to B-Cell receptor stimulation with a microRNA/mRNA signature associated with MYC activation and cell cycle progression.

Authors:  Valerie Pede; Ans Rombout; Jolien Vermeire; Evelien Naessens; Pieter Mestdagh; Nore Robberecht; Hanne Vanderstraeten; Nadine Van Roy; Jo Vandesompele; Frank Speleman; Jan Philippé; Bruno Verhasselt
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

9.  Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders.

Authors:  A Perrot; C Pionneau; N Azar; C Baillou; F M Lemoine; V Leblond; H Merle-Béral; M-C Béné; R Herbrecht; S Bahram; L Vallat
Journal:  Blood Cancer J       Date:  2012-09-07       Impact factor: 11.037

10.  Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.

Authors:  Joe Taylor; Alison M Yeomans; Graham Packham
Journal:  Explor Target Antitumor Ther       Date:  2020-02-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.